Assessments by patients with schizophrenia and psychiatrists of relative risk of research procedures

Psychiatric Services

Volumn 57, Issue 11, 2006, Pages 1629-1635

  Roberts, Laura Weiss ^a   Warner, Teddy D ^b   Hammond, Katherine Green ^b   Dunn, Laura B ^c  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

^b UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MEDICAL PRACTICE; MEDICAL RESEARCH; PATIENT ASSESSMENT; PSYCHIATRIST; QUESTIONNAIRE; RISK FACTOR; SCHIZOPHRENIA; X RAY ANALYSIS;

EID: 33751351802     PISSN: 10752730     EISSN: None     Source Type: Journal    
DOI: 10.1176/ps.2006.57.11.1629     Document Type: Article

References (56)

1. Knapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophrenia Bulletin 30:279-293, 2004
2. Diagnostic and Statistical Manual of Mental Disorders-Text Revision, 4th ed. Washington, DC, American Psychiatric Association, 2000
3. Freedman R: Schizophrenia. New England Journal of Medicine 349:1738-1749, 2003
4. Uhl GR, Grow RW: The burden of complex genetics in brain disorders. Archives of General Psychiatry 61:223-229, 2004
5. Wirshing DA, Pierre JM, Erhart SM, et al: Understanding the new and evolving profile of adverse drug effects in schizophrenia. Psychiatric Clinics of North America 26:165-190, 2003
6. Miyamoto S, Duncan GE, Marx CE, et al: Treatments for schizophrenia: a critical review of pharmacology and mechanisms of action of antipsychotic drugs. Molecular Psychiatry 10:79-104, 2005
7. Tandon R, Jibson MD: Pharmacologic treatment of schizophrenia: what the future holds. CNS Spectrums 6:980-984, 2000
8. Dunn LB, Candilis PJ, Roberts LW: Emerging empirical evidence on the ethics of schizophrenia research. Schizophrenia Bulletin 32:47-68, 2006
9. Roberts LW, Warner TD, Green Hammond KA, et al: Views of people with schizophrenia regarding aspects of research: study size and funding sources. Schizophrenia Bulletin 32:107-115, 2006
10. Roberts LW, Green Hammond KA, Hoop J: An inverse relationship between perceived harm and participation willingness in schizophrenia research protocols. American Journal of Psychiatry 163:2002-2004, 2006
11. Roberts LW, Dunn LB, Green Hammond KA, et al: Do research procedures pose relatively greater risk for healthy persons than persons with schizophrenia? Schizophrenia Bulletin 32:153-158, 2006
12. Roberts LW: Ethics and mental illness research. Psychiatric Clinics of North America 25:525-545, 2002
13. Federman DD, Hanna KE, Rodriguez LL (eds): Responsible Research: A Systems Approach to Protecting Research Participants. Washington, DC, Institute of Medicine Committee on Assessing the System for Protecting Human Research Participants, National Academies Press, 2002
14. Carpenter WT Jr, Gold JM, Lahti AC, et al: Decisional capacity for informed consent in schizophrenia research. Archives of General Psychiatry 57:533-538, 2000
15. Dunn LB, Jeste DV: Problem areas in the understanding of informed consent for research: study of middle-aged and older patients with psychotic disorders. Psychopharmacology 171:81-85, 2003
16. Emanuel EJ, Wendler D, Grady C: What makes clinical research ethical? JAMA 283:2701-2711, 2000
17. Pincus H, Lieberman J, Ferris S: Ethics in Psychiatric Research: A Resources Manual for Human Subjects Protection. Washington, DC, American Psychiatric Press, 1999
18. The Belmont Report: Ethical Principles and Guidelines for the Protection of Human Subjects of Research. Washington, DC, National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, 1979
19. Roberts LW: Ethical dimensions of psychiatric research: a constructive, criterion-based approach to protocol preparation: the research protocol ethics assessment tool (RePEAT). Biological Psychiatry 46:1106-1119, 1999
20. Code of Federal Regulations, Title 45: Public Welfare. Part 46: Protection of Human Subjects (Subpart C). Washington, DC, Department of Health and Human Services, 1991
21. Roberts LW: The ethical basis of psychiatric research: conceptual issues and empirical findings. Comprehensive Psychiatry 39(3):99-110, 1998
22. Roberts LW, Warner TD, Brody JL, et al: Patient and psychiatrist ratings of hypothetical schizophrenia research protocols: assessment of harm potential and factors influencing participation decisions. American Journal of Psychiatry 159:573-584, 2002
23. Kim SYH: Benefits and burdens of placebos in psychiatric research. Psychopharmacology 171:13-18, 2003
24. Levine RJ: Ethics and Regulation of Clinical Research. Baltimore, Urban and Schwartzenberg, 1986
25. Bogardus ST Jr, Holmboe E, Jekel JF: Perils, pitfalls, and possibilities in talking about medical risk. JAMA 281:1037-1041, 1999
26. Silverman HJ, Luce JM: Protecting subjects with decisional impairment in research: the need for a multifaceted approach. American Journal of Respiratory and Critical Care Medicine 169:10-14, 2004
27. Appelbaum PS: Drug-free research in schizophrenia: an overview of the controversy. IRB 18:1-5, 1996
28. Appelbaum PS: Rethinking the conduct of psychiatric research. Archives of General Psychiatry 54:117-120, 1997
29. Biesecker BB, Peay HL: Ethical issues in psychiatric genetics research: points to consider. Psychopharmacology 171:27-35, 2003
30. Carpenter W: The schizophrenia ketamine challenge study debate. Biological Psychiatry 46:1081-1091, 1999
31. Carpenter WT, Schooler NR, Kane JM: The rationale and ethics of medication-free research in schizophrenia. Archives of General Psychiatry 54:401-407, 1997
32. Lloyd AJ, Hayes PD, Bell PRF, et al: The role of risk and benefit perception in informed consent for surgery. Medical Decision Making 21:141-149, 2001
33. Miyamoto S, LaMantia AS, Duncan GE, et al: Recent advances in the neurobiology of schizophrenia. Molecular Interventions 3:27-39, 2003
34. Wendler D, Belsky L, Thompson KM, et al: Quantifying the federal minimal risk standard: implications for pediatric research without a prospect of direct benefit. JAMA 294:826-832, 2005
35. Wirshing DA, Wirshing WC, Marder SR, et al: Informed consent: assessment of comprehension. American Journal of Psychiatry 155:1508-1511, 1998
36. Stiles PG, Poythress NG, Hall A, et al: Improving understanding of research consent disclosures among persons with mental illness. Psychiatric Services 52:780-785, 2001
37. Dunn LB, Lindamer LA, Palmer BW, et al: Improving understanding of research consent in middle-aged and elderly patients with psychotic disorders. American Journal of Geriatric Psychiatry 10:142-150, 2002
38. Rosenstein DL, Miller FG: Ethical considerations in psychopharmacological research involving decisionally impaired subjects. Psychopharmacology 171:92-97, 2003
39. Roberts LW, Warner TD, Nguyen KD, et al: Schizophrenia patients' and psychiatrists' perspectives on ethical aspects of symptom re-emergence during psychopharmacological research participation. Psychopharmacology 171:58-67, 2003
40. Owen MJ, Williams NM, O'Donovan MC: The molecular genetics of schizophrenia: new findings promise new insights. Molecular Psychiatry 9:14-27, 2004
41. Riley B: Linkage studies of schizophrenia. Neurotoxicity Research 6:17-34, 2004
42. Malhotra AK, Murphy GM Jr, Kennedy JL: Pharmacogenetics of psychotropic drug response. American Journal of Psychiatry 161:780-796, 2004
43. Gribble JN: Informed consent documents for BRCA1 and BRCA2 screening: how large is the readability gap? Patient Education and Counseling 38:175-183, 1999
44. Green MJ, Botkin JR: "Genetic exceptionalism" in medicine: clarifying the differences between genetic and nongenetic tests. Annals of Internal Medicine 138:571-575, 2003
45. Roberts LW, Warner TD, Geppert CM, et al: Employees' perspectives of ethically important aspects of genetic research participation: a pilot study. Comprehensive Psychiatry 46:27-33, 2005
46. Roberts LW, Geppert CM, Warner TD, et al: Perspectives on use and protection of genetic information in work settings: results of a preliminary study. Social Science Medicine 60:1855-1958, 2005
47. Geppert CM, Roberts LW: Ethical issues in the use of genetic information in the workplace: a review of recent developments. Current Opinion in Psychiatry 18:518-534, 2005
48. Grover S: The psychological dimension of informed consent: dissonance processes in genetic testing. Journal of Genetic Counseling 12:389-403, 2003
49. Shore D, Berg K, Wynne D, et al: Legal and ethical issues in psychiatric genetic research. American Journal of Medical Genetics 48:17-21, 1993
50. Warner TD, Geppert CM, Massone J, et al: Views of ten chief residents on professionalism and ethics training. Annals of Behavioral Science and Medical Education 12:12-20, 2006
51. Roberts LW, Warner TD, Green Hammond KA: Coexisting commitments to ethics and human research: a preliminary study of the perspectives of 83 medical students. American Journal of Bioethics 5 (6):W1-W7, 2005
52. Roberts LW, Geppert CM, Warner TD, et al: Bioethics principles, informed consent, and ethical care for special populations: curricular needs expressed by men and women physicians-in-training. Psychosomatics 46:440-450, 2005
53. Roberts LW, Green Hammond KA, Kaminsky A, et al: Teaching medical students to discern ethical problems in human clinical research studies. Academic Medicine 80:925-930, 2005
54. Roberts LW, Geppert CM, Warner TD, et al: On the way to becoming a good doctor: perceived need for ethics training focused on practical and professional development topics. Academic Psychiatry 20:301-309, 2005
55. Scherer DG, Brody JL, Annett RD, et al: Financial compensation to adolescents for participation in biomedical research: adolescent and parent perspectives in seven studies. Journal of Pediatrics 146:552-558, 2005
56. Hammann J, Cohen R, Leucht S, et al: Do patients with schizophrenia wish to be involved in decisions about their medical treatment? American Journal of Psychiatry 162:2382-2384, 2005